We will systematically evaluate clinical outcomes over time in patients with HER2-positive advanced breast cancer from both interventional clinical trials and observational studies and compare patient characteristics, study characteristics, and outcomes within and between these study design types. This evidence concerns the gene ERBB2 and breast carcinoma.